Ways to improve the system of financial inclusion of medications for population of the Russian Federation

Written by Khafisianova R.Kh., Burykin I.M., Aleeva G.N.

  UDK: 615.1:615.22:338.5 | DOI: 10.17238/PmJ1609-1175.2019.2.28–32 | Pages: 28–32 | Full text PDF | Open PDF 


Objective is to define determinants of financial inclusion of medications to treat diseases of cardiovascular system after enaction of state price registration.
Methods: To assess the cost per unit it was used an approach based on defined daily dose (DDD). For the study we selected basic medications intended to treat disease of cardiovascular system (category АТХ). According to DDD we calculated the price DDD (pDDD). For the analysis we created a database of registered prices for medications of pharma producers for 2010–2016. We determined the evaluations of general totality, maximal and minimal rate and dynamics of prices during test period.
Results: It was established that movement of medications prices from 2010 to 2016 had been ambiguously changing and had been similar to rates of Federal State Statistics Service, but since 2015 difference have been registered as well. Conclusion: It is necessary to improve the system of financial inclusion of medications for the population to treat cardiovascular diseases.

Links to authors:

R.Kh. Khafisianova1, I.M. Burykin1, G.N. Aleeva2
1 Kazan State Medical University (49 Butlorov St. Kazan 420012 Russian Federation),
2 Nizhpharm Joint-Stock Company (7 Salganskaya St. Nizhny Novgorod 603950 Russian Federation)

1. Aleeva G.N., Zhuravleva M.V., Burykin I.M. Pharmacoeconomical analysis of the effectiveness of cardiostatin in the treatment of hypercholesterolemia // Clinical Pharmacology and Therapy. 2009. No. 6. P. 72–73.
2. VNOK. National Clinical Guidelines. Moscow: Silitseya-Poligraf, 2008. 512 p.
3. Ziganshina L.E., Magsumova D.R., Kuchaeva A.V. [et al.]. ATC/ DDD classification system in pharmacoepidemiological studies // Qualitative Clinical Practice. 2004. No. 1. P. 28–33.
4. Kontsevaya A.V., Kalinina A.M., Koltunov E.I., Oganov R.G. Socio-economic damage from acute coronary syndrome in the Russian Federation // Rational Pharmacotherapy in Cardiology. 2011. Vol. 2, No. 7. P. 158–166.
5. Lozovskaya A. Why is the availability of medicines for the population reduced? // Pharmacy business. 2011. No. 1–2.
6. Smolina V.A., Pashko O.D. Availability of pharmaceutical care to the population of Saratov region // Bulletin of Medical Internet Conferences. 2013. Vol. 3, No. 12. P. 1362–1364.
7. Tkachenko O.V. The selection, purchase and consumption of drugs: the experience of sociological research // Modern Research of Social Problems. 2013. No. 6. doi: 10.12731/2218-7405-2013- 6-53 (date of access: 23.01.2019).
8. Khafizyanova R.Kh., Burykin I.M., Aleeva G.N. Mathematical statistics in experimental and clinical pharmacology. Kazan: Meditsina. 2006. 374 p.
9. Cameron A., Ewen M., Ross-Degnan D. [et al.]. Medicine prices, availability, and affordability in 36 developing and middleincome countries: a secondary analysis // Lancet. 2009. Vol. 373, No. 9659. P. 240–249.
10. How to develop and implement a national drug policy. 2nd ed. Geneva: World Health Organization, 2001. 83 p.
11. Introduction to drug utilization research. Geneva: WHO, 2003. 84 p.
12. Kanavos P., Reinhardt U. Reference pricing for drugs: Is it compatible with U.S. Health Care? // Health Aff. 2003. Vol. 22, No. 3. P. 16–30.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.